What the business is
AI platform that screens every adult inpatient's record nightly for undiagnosed conditions such as malnutrition and delirium, then writes a risk score into the care team's workflow.
The bet
Hospitals will pay for AI that reads clinicians' notes to catch undiagnosed conditions, signing outcome-based contracts that pay multiples on validated ROI.
Starting capital
$38M: an $8M seed co-led by Sequoia Capital and First Round Capital and a $30M Series A led by Hummingbird Ventures; valuation undisclosed.
How it started
Siblings Jemima and Josiah Meyer founded the company in South Africa in 2022; Jemima had built a clinical nutrition tool for dietitians, which became the first product.
What happened
It pivoted to a general-purpose screening platform, grew from three hospital partners to more than 50 in a year, and built programs for aspiration pneumonia, pressure ulcers and congestive heart failure readmission that are still in clinical validation.
What has to be true
The most telling clinical signs sit in free-text notes, not structured fields — reading them at scale is the product.
Pivoting from a single-condition nutrition tool to a general screening platform widened the same wedge into dozens of conditions.
Outcome-based contracts de-risk the buyer: the vendor only gets paid multiples when the hospital's own finance team validates the ROI.
Growing from three to more than 50 hospital partners in a year, with customers like Penn Medicine and Cedars-Sinai, gave the raise proof of demand.
What can be applied
Sell to hospitals on their own validated numbers: let the finance team attribute the ROI and guarantee multiples of the price, and procurement becomes arithmetic.
Aftermath
As of the 7 October 2026 report, the fresh capital is earmarked for engineering, product, sales and customer success as Healthleap adds conditions — Meyer says it ultimately wants to cover more than 40 major conditions and expand into outpatient and home care. Programs for aspiration pneumonia, pressure ulcers and heart-failure readmission risk were still undergoing clinical validation.
FOLLOW THE EVIDENCE